Combining cell therapy with biopolymer films improves wound healing in a juvenile dermatomyositis patient

Terapia celular combinada com membranas de biopolímeros melhora a cicatrização de úlceras em paciente com dermatomiosite juvenil

ABSTRACT

Introduction: Juvenile dermatomyositis (JDM) is a systemic disease that affects children’s proximal musculature and skin. The ulcerated stage of the disease is a therapeutic challenge.

Objective: To evaluate the improvement of ulcerated stage of JDM caused by the use of cell therapy.

Methods: Co-culture of autologous fibroblasts and keratinocytes, application of these cells in ulcers in conjunction with fibrin glue, and placement of chitosan-alginate or chitosan-xanthan membrane on the lesions.

Results: Less than 12 hours after therapy, the patient reported complete cessation of pain and, within 2 days, healing tissue emerged. Some of the ulcers were almost completely healed by the end of the 1st week, and some of the calcinoses disappeared. This technique does not cure the disease, however it improves the patient’s quality of life, and it is possible to cryopreserve healthy cells to treat new lesions. Given the fact that the cells are of autologous origin, the risk of rejection is eliminated. Furthermore, this procedure does not require debridement of the lesions or hospitalization.

Conclusions: The application of autologous cultures of fibroblasts and keratinocytes in ulcers is already considered an effective treatment in patients with burns and other skin wounds, and has now also been proven effective in the treatment of wounds in JDM.

Keywords: Calcinosis; Cell-and tissue-based therapy; Dermatomyositis; Fibroblasts; Keratinocytes; Polysaccharides; Wound healing

RESUMO

Introdução: Dermatomiosite juvenil (DMJ) é doença sistêmica que afeta a musculatura proximal e a pele de crianças. A doença ulcerada é um desafio terapêutico.

Objetivo: Avaliar a melhora da doença ulcerada na DMJ, pelo uso de terapia celular.

Métodos: Realização de cocultura de fibroblastos e queratinócitos autólogos e aplicação dessas células nas úlceras juntamente com cola de fibrina e colocação de membrana de quitosana-alginato ou quitosana-xantana sobre as lesões.

Resultados: Menos de 12 horas após a terapia, o paciente referiu completa eliminação da dor e, dentro de dois dias, estava presente tecido de cicatrização. Algumas das úlceras estavam quase completamente cicatrizadas no final da primeira semana, e algumas das calcinoses desapareceram. Essa técnica não cura a doença, mas melhora a qualidade de vida, sendo possível criopreservar as células saudáveis do paciente para tratar novas lesões. Sendo as células de origem autológica, elimina-se o risco de rejeição. Além disso, esse procedimento não necessita de debridamento das lesões nem hospitalização.

Conclusões: A aplicação de culturas autólogas de fibroblastos e queratinócitos em úlceras já é considerada tratamento efetivo em pacientes com queimaduras e outras feridas cutâneas e, agora mostrou-se também eficaz no tratamento de feridas na DMJ.

Palavras-chave: Calcinoses; Cicatrização; Dermatomiosite; Fibroblastos; Polissacarídeos; Queratinócitos; Terapia baseada em transplante de células e tecidos

DOI: http://www.dx.doi.org/10.5935/scd1984-8773.20181011129
INTRODUCTION

Juvenile dermatomyositis (JDM) is a rare and severe systemic condition that affects primarily the proximal muscles and skin in children, with a prevalence of three per million in the population. Its etiology is not completely understood, but it is suggested that it is caused by an autoimmune reaction in individuals genetically susceptible to environmental triggers. JDM's cutaneous manifestations can be severe and difficult to treat, with significant long-term morbidity.

Calciosis, characterized by the formation of calcium deposits in the skin, usually affects 10% to 70% of pediatric patients with JDM, being generally diagnosed in the first three years of the disease. Together with dermatomyositis itself, calciosis can negatively impact in the patient's quality of life, resulting in weakness, functional disability, muscular atrophy, cutaneous ulcers and, consequently, local pain and secondary infections. Dystrophic calcifications occur where there is tissue damage, with normal serum levels of calcium and phosphorus. Although they can appear in any part of the body, the areas most commonly affected are elbows, knees, trunk, hands, feet, buttocks and head. Calciosis is usually painless; however, it can be associated to tenderness on palpation and pain with compression, evidencing panniculitis and ulcerations on histopathology. There is deposition of calcium on the skin surface, making it susceptible to infections.

In juvenile dermatomyositis, the severity of the disease can be related to cutaneous calciosis, delay in starting treatment and, potentially, to genetic polymorphisms of TNF-α-308. Despite the lack of data on the pathogenesis of calciosis in JDM, a possible mechanism is calcium release from mitochondria of muscle cells affected by the myopathy. Macrophages, pro-inflammatory cytokines and defects in regulatory proteins of calcium can be also suggested, as well as vascular ischemia, which also has a role in calciosis. The deposition of calcium can occur in the subcutaneous tissue or in muscles and then ulcerate, draining a chalky substance. Ulcerated disease is severe and can be fatal, reflecting the importance of cutaneous vascular disorders, with tissue hypoxia and necrosis.

As calciosis tends to worsen with the progression of JDM, early and aggressive therapeutic approach has been suggested as an option to reduce cutaneous and muscular sequelae. Multiple medications have been used, such as corticosteroids, methotrexate, bisphosphonates, probenecid, warfarin, aluminium hydroxide, colchicine, diltiazem, infliximab, immunoglobulin, hydroxychloroquine, cyclophosphamide and thalidomide, but also playing an important role in promoting healing. Formation of granulation tissue and reepithelization, followed by angiogenesis and continuous deposition of collagen fibers, limiting scar formation and tissue retraction, were seen with the use of chitosan, for example. The association of multiple polymers is also relevant, since it allows for the development of dressings with improved properties, such as enhanced fluid absorption. Relevant in vivo studies were described recently on the use of membranes manufactured by the association of chitosan with xanthan and alginate for the treatment of cutaneous ulcers in Wistar rats, with or without the combination or mesenchymal cells, demonstrating a potential that could be used as dressings in JDM lesions.

The objective of this study was to demonstrate an alternative therapy for the treatment of chronic ulcers in JDM patients with calciosis that are not responsive to conventional treatments, using culture of autologous cells and subsequently covered with membranes of biocompatible polysaccharides.

METHODS

This study was approved by the Committee of Ethics in Research of the Universidade Estadual de Campinas (Unicamp – CEP: 444.726).

Case description and sample collection

A male, 18-year-old patient, diagnosed with JDM since 5 years of age, undergoing conventional treatment with methotrexate and corticosteroids, with universal calciosis and chronic cutaneous ulcers, some with exposure of bone, was submitted to skin biopsy of a non-ulcerated on the right arm after signing a consent form. Fragments of approximately 2cm² were collected and stored in saline, antibiotic and antifungal (Anti-Anti 15240, batch 577999, GIBCO/Invitrogen) until being transferred to culture jars. During the whole research, the patient maintained the previous systemic treatment.

Cell culture of skin fragments

The skin fragments were placed into culture jars with a keratinocyte medium (KSF-M-GIBCO/Invitrogen) supplemented with 10% of fetal bovine serum (FBS - LGC Biotechnology) and L-glutamine 0.2mg/ml, penicillin 100UI/mL and streptomycin 0.1mg/ml (GIBCO/Invitrogen), until processing. Subsequently, the fragments were transferred to Petri dishes with trypsin 2.5% and EDTA solution 0.1% (GIBCO/Invitrogen) and incubated at 37°C e 5% CO₂ for 3 hours, when the dermis was separated from the epidermis. Trypsin was neutralized with a KSF-M medium supplemented with 10% FBS. The supernatant (containing dermal and epidermal cells) was filtered (40mm Falcon/Corning) and centrifuged for 10 minutes at 400G.
The cell pellet was resuspended in culture medium and transferred to culture jars with a concentration of 1x105 cells/ml in 2ml of specific culture medium for each cell type and then incubated at 37°C and 5% CO₂. Keratinocytes were cultivated in KSFM medium (KSFM-GIBCO/Invitrogen) supplemented with 10% fetal bovine serum (FBS - LGC Biotechnology) and L-glutamine 0.2mg/ml, penicillin 100UI/ml and streptomycin 0.1mg/ml (GIBCO/Invitrogen). Culture media were changed three times per week. When the cells reached confluence, cultures were trypsinized with trypsin and EDTA solution for 10 minutes at 37°C and 5% CO₂. As previously, trypsin was neutralized with fetal bovine serum 10%. This procedure was performed until a minimal amount was obtained for each cell type, approximately 5x106 keratinocytes and 10x106 fibroblasts. The whole process took between 21 and 30 days. Cells were cryopreserved in fetal bovine serum and DMSO solution at -80°C.

The whole process involving cell manipulation was performed in a clean room (class 10,000 ISO 7 - ISO 14644-1).

**Membrane preparation**

The preparation of membranes followed a technique already established at the Department of Material Engineering and Bioprocesses, Faculdade de Engenharia Química, Universidade Estadual de Campinas.

Membranes were obtained according to adaptations to methods established by Rodrigues et al.,22 Bueno and Moraes23 and adapted by Pires and Moraes,24 in the case of chitosan-alginate devices (C-A), based in procedures developed by Veiga and Moraes25 and Bellini et al.26 for the chitosan-xanthan membranes (C-X).

Chitosan with deacetylation degree of 96% (Sigma-Aldrich, batch number 109K0043V), medium viscosity sodium alginate from *Macrocystis pyrifera* (Sigma-Aldrich, batch number 058K0126), xanthan gum (Sigma-Aldrich, batch number 108K0038), glacial acetic acid, calcium chloride dehydrate and sodium hydroxide (Merck); besides, the water used was distilled and deionized in a Milli-Q system (Millipore).

Chitosan and alginate membranes were prepared with the addition of quantities of 180ml of 1% chitosan solution (m/v) dissolved in 2% acetic acid (v/v) in 360ml 0.5% alginate aqueous solution (m/v) at the flow of 200ml/h in the stainless steel reactor, maintained at 25°C, under stirring of 500rpm. After mixing the solutions, the stirring intensity was increased to 1000rpm for 10 additional minutes. Afterwards, 26ml of 2M NaOH aqueous solution were added to increase pH to 7, maintaining stirring for 10 more minutes. Afterwards, 7.2ml of 2% CaCl₂ aqueous solution (m/v) were added to reticulate alginate carboxyls that did not form complexes with chitosan. The mixture obtained was deaerated for 120 minutes, transferred (in quantities of equal masses) into four polystyrene Petri dishes (diameter of 15cm) and dried in a dryer at 60°C for 6 hours. After drying, the membranes were immersed in 150ml aqueous solution of 2% CaCl₂ (m/v) for 30 minutes for reticulation of free carboxyls leftover form alginate and then washed twice for 30 minutes with 200ml of deionized water. The final drying step was performed at room temperature for 24 hours.

In the case of chitosan and xanthan gum membranes, 200ml of aqueous solution of xanthan gum 1.5% (m/v) were added to 200ml of 1.5% chitosan solution (m/v) dissolved in 1.5% acetic acid (v/v) with a flow of 30ml/h, at 25°C and under stirring (1000rpm). After, the suspension was deaerated and the mixture was transferred into a polystyrene dish of 15cm diameter and the material was dried at 37°C for a variable period of 24 to 48 hours. The membrane was washed twice for 30 minutes with 200ml deionized water, once with 250ml of 10mM Hepes buffer (Sigma-Aldrich) to neutralize pH and, finally, with 500ml deionized water. A final drying step was performed at room temperature for 24 hours, securing the edges to prevent shrinking of the membrane.

The membranes were sterilized with Oxyfume 30 (30% ethylene oxide and 70% CO₂) at 40°C for 8 hours, with relative humidity of 30% to 80% by the Central de Esterilização Comércio e Indústria Ltda – Accel (Campinas, SP). Transmission electron microscopy was performed to verify behavior of the cells in the membrane (Figure 1).

**Patient treatment**

The cells were thawed and cultivated for at least 72 hours before application. On the day of application, the cells were trypsinized, washed and counted according to protocols previously described by Rehder et al.,13 Souto et al.,27,15 Bosnardo16 and Dinato et al.27 A culture of fibroblasts of a total of 1x107 cells was prepared. For the application, cells were sprayed with fibrin glue (Beriplast P – CSL-Behring) over the ulcer bed under antiseptic conditions, in an outpatient setting (Figure 2).

After spraying the cells, the polysaccharide membranes previously diluted with saline were placed on the ulcer (Figure 3), in order to protect the area against agents that could remove the graft, aiming at aiding the healing process.

The patient was followed for 20 months, every 7 days in the first month, and every 15 or 30 days thereafter. New applications were performed according to the patient’s response, in a total of 7. Photographic documentation was made with Nikon D5100 camera, using a ruler to determine the total area of the ulcer, delineating its borders. The images were processed with the software Image J2, and the differences in the values of the areas were determined for each ulcer using the software GraphPad Prism5.

A quality of life questionnaire (SF-36) was also used before and at the end of the treatment.

**RESULTS**

The patient had multiple cutaneous ulcers, ranging from 0.5cm² to 8cm², distributed all over the body but mainly on the...
Figure 1: Transmission electron microscopy: A – chitosan and xanthan membrane with cells (white arrows) (12930x); B – chitosan and alginate membrane (1293x); C – chitosan and alginate membrane (3597x)

Figure 2: Clinical aspect of the wounds. A, B, C – clinical presentation of JDM patient with multiple lesions

lower limbs (Figure 2). The lesions selected for the treatment were the larger and the deeper, which caused more discomfort. The healing process was documented with photographs in weeks zero, 3, 21, 28, 42, 64 (Figure 3) and 79 (Figure 4).

Less than 12 hours after the application of cells and membranes, the patient reported total improvement of the pain and, in two days, the healing process started. Soon thereafter, a shiny film was seen on the surface of the ulcers. Some days later, an intense exudate, attributed to fibrin, granulation tissue and crust was seen in some lesions, with subsequent centripetal closure. Some wounds were completely closed after one week of treatment.

The healing rate achieved was above 95%, with continuous improvement even after 5 months of the last application (Graph 1). The patient did not have any more pain on the treated areas, with significant improvement in quality of life (Graph 2). Interestingly, the calcinosis disappeared even in areas that were not treated directly.

DISCUSSION

JDM is a rare autoimmune disease that affects primarily the muscles and the skin. The main treatment is with high doses of corticosteroids combined to other immunosuppressant drugs. Approximately 30% of patients cannot control the disease, despite multiple interventions, as seen in our patient. The application of stem cells was described as a last resource in the treatment of patients with autoimmune diseases refractory to treatment but persistence of cutaneous disease, including calcinosis and contractures.

Treatment of the ulcerated and refractory disease is very complex, and autoimmune diseases are quite challenging. Tissue engineering focused on autologous keratinocytes and fibroblasts has been used in the treatment of cutaneous ulcers since the 1980s. The technique was initially tested in burn patients, with good results. Then improved healing was seen in vascular and diabetic ulcers. In recent years, tissue engineering significantly advanced with this goal, and one of the trends in dermatology is the use of combined biomaterials with biopolymers and cells fulfilling biosafety requirements and that are active in the type of wound treated. Positive and relevant results were seen in our JDM patient after the application of autologous fibroblasts and keratinocytes, applied with fibrin glue, followed by the coverage with membranes made of chitosan with xanthan or alginate.

The protection provided by chitosan–alginate and chitosan–xanthan dressings with negative stimuli from the environment plays a role in the healing process. According to Wang et al., the optimal dressing should be flexible and able to control local water loss. It must be resistant to bacterial infection therefore preventing sepsis, have adequate adherence on the ulcer, as well as not being antigenic, non-toxic and easy to apply and
From the engineering perspective, the material for the dressing should also have adequate mechanical properties so as to maintain its integrity during use. Rates of water evaporation are also important, both for maintaining adequate humidity in the wound bed and to avoid unwanted accumulation of secretions. Both membranes used in this study achieved this goal, being effective in the contribution to expedite tissue regeneration and promote speedy recovery. Besides, membranes are clear, which allows observation of the wound bed, without needing to be removed.

The complex chitosan-alginate seems to have a positive action in the process of tissue remodeling in scars, increasing the rates of collagen synthesis, while also improving compaction of new fibers and promoting the presence of mature fibroblasts. Moreover, these membranes seem to stimulate and regulate multiple phases of the healing process, being useful in the treatment of cutaneous ulcers. Both collagen synthesis and modulation of wound contraction by chitosan-alginate membranes can result in a fast closure of the lesion. Similar results were seen on chitosan-xanthan membranes associated to mesenchymal cells.

The role of fibrin glue is not clear in this case. The product is a biological adhesive that works by simulating the exudative phase of healing, frequently used in plastic surgery, as well as organ transplants. In this case, our hypothesis of its possible benefit is by the improved cell and membrane adherence to the lesions, and by its hemostatic and antibacterial actions. Under normal circumstances, soon after the injury, fibrin and fibronectin...
Cell therapy with autologous fibroblasts and keratinocytes was used in this study for a more effective treatment of ulcers in JDM patients with better functional and aesthetic results, as well as a faster recovery and elimination of pain, allowing the patient to return to his studies. The development of a strategy based on cell therapy represents a progress in the treatment of ulcers of different etiologies, and the use of C-A and C-X membranes associated to autologous cells is very advantageous because membranes can function as a physical barrier, preventing external contamination, besides having a possible role in healing. There was no difference of performance in the healing rates with different membranes.

The implants described here were effective when compared to conventional treatments of skin grafting with healthy donor sites, even if some ulcers did not completely heal, probably due to their extension and depth. Cell cultures can be cryopreserved and eventually used in a new application. Autologous cells are great candidates, because with them the risk of rejection is eliminated. Another positive aspect is not needing hospitalization or debridement of the lesions.

CONCLUSION

This was the first case described showing the use of cultures of autologous fibroblasts and keratinocytes associated to chitosan-alginite or chitosan-xanthan membranes for the treatment of cutaneous ulcers associated to juvenile dermatomyositis.

In this study, we demonstrated an effective strategy for the treatment of cutaneous disease caused by juvenile dermatomyositis, even though it was not completely cured. Maybe the combination of stem cell transplant with autologous cutaneous cells could be the cure for a patient like ours, who presents with extensive and debilitating disease. Although it as a sophisticated and restricted technique, it proved to be a valid therapeutic strategy that can be used in JDM and in ulcers with other etiologies.

REFERENCES


DECLARATION OF PARTICIPATION:

Paula Tavares Colpas | ORCID 0000-0002-1389-0749
Main researcher of the article, responsible for literature review, writing, proofreading and final approval.

Paulo César Martins Alves | ORCID 0000-0002-6833-0343
Responsible for cell culture and manuscript review.

Carolina Caliari Oliveira | ORCID 0000-0001-7906-9809
Responsible for cell culture and manuscript review.

Ana Luiza Resende Pires | ORCID 0000-0001-8247-6288
Responsible for the production of membranes and manuscript review.

Angela Maria Moraes | ORCID 0000-0002-5813-332X
Supervision and study review.

Maria Beatriz Puzzi | ORCID 0000-0001-8248-7884
Supervision and study review.